Kamata Yoichi, Hoshi Hidenobu, Choki Hayato, Kozaki Shunji
Department of Veterinary Science, College of Agriculture, Osaka Prefecture University, Gakuen-cho, Sakai, Osaka, Japan.
J Vet Med Sci. 2002 Sep;64(9):767-71. doi: 10.1292/jvms.64.767.
A monoclonal antibody, named C302, was prepared and characterized against botulinum ADP-ribosyltransferase C3 exoenzyme that inactivates RhoA GTP-binding protein, resulting in the neurite outgrowth of human neuroblastoma GOTO cells. C302 bound not to the smaller fragments derived from the protease-treated C3 exoenzyme but to the intact C3 exoenzyme. It seems that the C302 epitope may depend on the three-dimensional structure of C3 exoenzyme molecule. C302 depressed the enzymatic and biological actions of C3 exoenzyme. The dose-dependent depression pattern of C302 on the enzyme activity was similar to that to the biological one. C302 turned the neurite-bearing shape of the C3 exoenzyme-treated GOTO cells into the intact shape. By using of C302 mAb and C3 exoenzyme, the research concerning GTP-binding proteins would be improved.